SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer
نویسندگان
چکیده
منابع مشابه
SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer
Immunotherapeutic strategies including the blockade of programmed death 1 (PD-1) receptors hold promise for the treatment of various cancers including non-small cell lung carcinoma (NSCLC). Preclinical data suggest that pre-existing tumor immunity is important for disease regression upon checkpoint blockade-based therapies. However, the nature of antigen-specific T-cell responses that correlate...
متن کاملImmunotherapy for Non-Small Cell Lung Cancer
Lung cancer is the leading cause of cancer-related mortality worldwide, and more than 80% of cases are of non-small cell lung cancer. Although chemotherapy and molecularly targeted therapy may provide some benefit, there is a need for newer therapies for the treatment of patients with advanced NSCLC. Immunotherapy aims to augment the recognition of cancer as foreign, to stimulate immune respons...
متن کاملTargeted therapies and immunotherapy in non-small-cell lung cancer
Non-small-cell lung cancer is still considered a difficult disease to manage because of its aggressiveness and resistance to common therapies. Chemotherapy remains the gold standard in nearly 80% of lung cancers, but clinical outcomes are discouraging, and the impact on median overall survival (OS) barely reaches 12 months. At the end of the last century, the discovery of oncogene-driven tumour...
متن کاملAdvances in immunotherapy for non-small cell lung cancer.
In most patients, lung cancer presents as advanced disease with metastases to lymph nodes and/or distant organs, and survival is poor. Lung cancer is also a highly immune-suppressing malignancy with numerous methods to evade antitumor immune responses, including deficiencies in antigen processing and presentation, release of immunomodulatory cytokines, and inhibition of T-cell activation. Advan...
متن کاملImmunotherapy and the Treatment of Non–Small Cell Lung Cancer
W ith more than 200,000 cases expected for 2016, lung cancer is the leading cause of cancer death in both men and women, accounting for more than one-quarter of all cancer deaths. “A lot of people don’t realize that lung cancer has a higher mortality than breast, prostate, and colorectal cancers combined,” said Suzanne Walker, CRNP, MSN, AOCN®, BC, of Abramson Center at Penn Presbyterian Medica...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: OncoImmunology
سال: 2013
ISSN: 2162-402X
DOI: 10.4161/onci.25205